Monoclonal Anti-Nipah Post Fusion glycoprotein Antibody, Human IgG1 (2B2) (MALS verified)
Selected Variant
NIN-M759-1mg
Size: 1 mg
Hendra virus (HeV) and Nipah virus (NiV) are henipaviruses discovered in the mid-to late 1990s that possess a broad host tropism and are known to cause severe and often fatal disease in both humans and animals. HeV and NiV infect host cells through the coordinated efforts of two envelope glycoproteins. The G glycoprotein attaches to cell receptors, triggering the fusion (F) glycoprotein to execute membrane fusion. G is a type II homotetrameric transmembrane protein responsible for binding to ephrinB2 or ephrinB3 (ephrinB2/B3) receptors. F is a homotrimeric type I transmembrane protein that is synthesized as a premature F0 precursor and cleaved by cathepsin L during endocytic recycling to yield the mature, disulfide-linked, F1 and F2 subunits. Upon binding to ephrinB2/B3, NiV G undergoes conformational changes leading to F triggering and insertion of the F hydrophobic fusion peptide into the target membrane. Subsequent refolding into the more stable post-fusion F conformation drives merger of the viral and host membranes to form a pore for genome delivery to the cell cytoplasm.
Product Specifications
Background
CAS Number
9007-83-4
Host
HEK293
Origin Species
Human
Target
Nipah Post Fusion glycoprotein
Conjugation
Unconjugated
Tag
Human IgG1 | Human Kappa
Stability
Purity
0.95
Bioactivity
Format
Powder
Buffer
PBS, pH7.4
Additives
Trehalose
Additionnal Information
Please see 'Shipping-and-Payments' sheet. Website: https://www.acrobiosystems.com/support/shipping-and-payments
Shipping Conditions
RT
Storage Conditions
-20°C
Package Size
1mg*1
Host or Source
HEK293
Species
Mouse
Preservative
Trehalose
Price
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog